Sinopharm Group Co. Ltd.

SEHK:1099 주식 보고서

시가총액: HK$63.2b

Sinopharm Group 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Wanyong Lian

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권n/a
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간4.2yrs

최근 관리 업데이트

Recent updates

Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Nov 06
Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business

Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Oct 04
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Aug 23
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Jul 27
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Jun 16
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

May 13
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Apr 22
Is Sinopharm Group (HKG:1099) A Risky Investment?

Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Mar 21
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital

Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Mar 06
Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Jan 31
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?

Is Sinopharm Group (HKG:1099) A Risky Investment?

Jan 15
Is Sinopharm Group (HKG:1099) A Risky Investment?

There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Dec 31
There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding

Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

Nov 29
Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)

If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Nov 14
If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity

Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Nov 01
Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?

Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Sep 20
Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sep 05
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Aug 18
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Aug 02
Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?

Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Jun 01
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Apr 26
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Feb 27
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Jan 19
Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger

Is Sinopharm Group (HKG:1099) A Risky Investment?

Nov 18
Is Sinopharm Group (HKG:1099) A Risky Investment?

Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Oct 03
Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jul 31
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Jul 10
Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

Jun 05
Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement

We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

Apr 11
We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Mar 21
A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)

Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Mar 03
Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Jan 09
Is Sinopharm Group (HKG:1099) Using Too Much Debt?

Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Dec 19
Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price

Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

Dec 01
Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Jun 06
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly

Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

May 24
Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value

Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

May 11
Sinopharm Group's (HKG:1099) Returns Have Hit A Wall

Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

Mar 20
Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?

We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

Mar 05
We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt

CEO

Wanyong Lian (53 yo)

less than a year

테뉴어

Mr. Wanyong Lian has been the Head of the investment management department of CNPGC since February 2008. Mr. Lian has over 20 years of working experience, all of which is management experience. Mr. Lian wa...

리더십 팀

이름위치테뉴어보상소유권
Wanyong Lian
President & Executive Directorless than a year데이터 없음데이터 없음
Xiaojuan Li
Chief Financial Officer3.7yrs데이터 없음데이터 없음
Yijian Wu
Secretary to the Board5.9yrs데이터 없음데이터 없음

3.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 1099 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Wanyong Lian
President & Executive Directorless than a year데이터 없음데이터 없음
Qiyu Chen
Non-Executive Vice Chairman14.5yrs데이터 없음데이터 없음
Dongjiu Li
Non-Executive Director3.4yrs데이터 없음데이터 없음
Xiaohui Guan
Chief Supervisor3.4yrs데이터 없음데이터 없음
Tak Lung Wu
Independent Non-Executive Director4.2yrsCN¥350.00k데이터 없음
Peiyu Li
Independent Non-Executive Director4.2yrsCN¥350.00k데이터 없음
Bingxiang Zhao
Non-Executive Chairmanless than a year데이터 없음데이터 없음
Deyong Wen
Non-Executive Director7.2yrs데이터 없음데이터 없음
Fangruo Chen
Independent Non-Executive Director5.9yrsCN¥350.00k데이터 없음
Rongli Feng
Non Executive Director4.4yrs데이터 없음데이터 없음
Weifeng Yu
Independent Non-Executive Director4.2yrsCN¥350.00k데이터 없음
Peng Wang
Non-executive Director1.2yrs데이터 없음데이터 없음

4.2yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 1099 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.